References
- Airaksinen M. M., Kari I. Beta‐carbolines, psychoactive compounds in the mammalian body. Part I: occurrence, origin and metabolism. Med. Biol. 1981a; 59(1)21–34, [PUBMED], [INFOTRIEVE]
- Airaksinen M. M., Kari I. Beta‐carbolines, psychoactive compounds in the mammalian body. Part II: effects. Med. Biol. 1981b; 59(4)190–211, [PUBMED], [INFOTRIEVE]
- Akiyama T. E., Gonzalez F. J. Regulation of P450 genes by liver‐enriched transcription factors and nuclear receptors. Biochim. Biophys. Acta 2003; 1619(3)223–234, [PUBMED], [INFOTRIEVE]
- Aklillu E., Persson I., Bertilsson L., Johansson I., Rodrigues F., Ingelman‐Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 1996; 278(1)441–446, [PUBMED], [INFOTRIEVE], [CSA]
- Al‐Dabbagh S. G., Idle J. R., Smith R. L. Animal modelling of human polymorphic drug oxidation–the metabolism of debrisoquine and phenacetin in rat inbred strains. J. Pharm. Pharmacol. 1981; 33(3)161–164
- Allorge D., Harlow J., Boulet O., Hayhurst G. P., Chowdry J., Roth E., Crewe K., Lo‐Guidice J. M., Lhermitte M., Broly F., Tucker G. T., Ellis S. W. In‐vitro analysis of the contribution of CYP2D6.35 to ultra‐rapid metabolism. Pharmacogenetics 2001; 11(8)739–741, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Alvan G., von Bahr C., Seidemann P., Sjoqvist F. High plasma concentrations of beta‐receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet 1982; 1(8267)333, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Alvan G., Bechtel P., Iselius L., Gundert‐Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 1990; 39(6)533–537, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ayesh R., Dawling S., Hayler A., Oates N. S., Cholerton S., Widdop B., Idle J. R., Smith R. L. Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality 1991; 3(1)14–18, [PUBMED], [INFOTRIEVE]
- Balant‐Gorgia A. E., Gex‐Fabry M., Balant L. P. Clinical pharmacokinetics of clomipramine. Clin. Pharmacokinet. 1991; 20(6)447–462
- Balemans M. G., Bary F. A., Legerstee W. C., Van Benthem J. Seasonal variations in HIOMT activity during the night in the pineal gland of 21 day old male wistar rats. J. Neural Transm. 1980; 49(1–2)107–116, [PUBMED], [INFOTRIEVE]
- Ball S. E., Ahern D., Scatina J., Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism, comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br. J. Clin. Pharmacol. 1997; 43(6)619–626, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bapiro T. E., Hasler J. A., Ridderstrom M., Masimirembwa C. M. The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem. Pharmacol. 2002; 64(9)1387, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bathum L., Johansson I., Ingelman‐Sundberg M., Horder M., Brosen K. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics 1998; 8(2)119–123, [PUBMED], [INFOTRIEVE], [CSA]
- Baxter G. S., Murphy O. E., Blackburn T. P. Further characterization of 5‐hydroxytryptamine receptors (putative 5‐HT2B) in rat stomach fundus longitudinal muscle. Br. J. Pharmacol. 1994; 112(1)323–331, [PUBMED], [INFOTRIEVE], [CSA]
- Beck O., Bosin T. R. Analysis of 5‐methoxytryptamine in brain by gas chromatography mass spectrometry. Biomed. Mass Spectrom. 1979; 6(1)19–22, [PUBMED], [INFOTRIEVE]
- Beck O., Jonsson G. In vivo formation of 5‐methoxytryptamine from melatonin in rat. J. Neurochem. 1981; 36(6)2013–2018, [PUBMED], [INFOTRIEVE]
- Beck O., Jonsson G., Lundman A. 5‐Methoxyindoles in pineal gland of cow, pig, sheep and rat. Naunyn‐Schmiedeberg's Arch. Pharmacol. 1981; 318(1)49–55, [CROSSREF]
- Beck O., Borg S., Lundman A. Concentration of 5‐methoxyindoles in the human pineal gland. J. Neural Transm. 1982; 54(1–2)111–116, [PUBMED], [INFOTRIEVE], [CSA]
- Beckmann J., Hertrampf R., Gundert‐Remy U., Mikus G., Gross A. S., Eichelbaum M. Is there a genetic factor in flecainide toxicity?. BMJ 1988; 297(6659)1316, [PUBMED], [INFOTRIEVE]
- Bertilsson L., Dahl M. L., Dalen P., Al‐Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 2002; 53(2)111–122, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bertilsson L., Lou Y. Q., Du Y. L., Liu Y., Kuang T. Y., Liao X. M., Wang K. Y., Reviriego J., Iselius L., Sjoqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin. Clin. Pharmacol. Ther. 1992; 51(4)388–397, [PUBMED], [INFOTRIEVE]
- Bertrand P. P., Kunze W. A., Furness J. B., Bornstein J. C. The terminals of myenteric intrinsic primary afferent neurons of the guinea‐pig ileum are excited by 5‐hydroxytryptamine acting at 5‐hydroxytryptamine‐3 receptors. Neuroscience 2000; 101(2)459–469, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Boess F. G., Monsma F. J., Jr., Carolo C., Meyer V., Rudler A., Zwingelstein C., Sleight A. J. Functional and radioligand binding characterization of rat 5‐HT6 receptors stably expressed in HEK293 cells. Neuropharmacology 1997; 36(4–5)713–720, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Borowsky B., Adham N., Jones K. A., Raddatz R., Artymyshyn R., Ogozalek K. L., Durkin M. M., Lakhlani P. P., Bonini J. A., Pathirana S., Boyle N., Pu X., Kouranova E., Lichtblau H., Ochoa F. Y., Branchek T. A., Gerald C. Trace amines: identification of a family of mammalian G protein‐coupled receptors. Proc. Natl. Acad. Sci. U. S. A. 2001; 98(16)8966–8971, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Botsch S., Gautier J. C., Beaune P., Eichelbaum M., Kroemer H. K. Identification and characterization of the cytochrome P450 enzymes involved in N‐dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol. Pharmacol. 1993; 43(1)120–126, [PUBMED], [INFOTRIEVE]
- Britt S. G., Gonias S. L., Sanders J. M., Vandenberg S. R. Agonist and antagonist activities of arylpiperazines at human platelet serotonin2 receptors. J. Pharmacol. Exp. Ther. 1988; 247(3)965–970, [PUBMED], [INFOTRIEVE], [CSA]
- Broly F., Meyer U. A. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3‐base‐pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 1993; 3(3)123–130, [PUBMED], [INFOTRIEVE]
- Brosen K., Gram L. F. First‐pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clin. Pharmacol. Ther. 1988; 43(4)400–406, [PUBMED], [INFOTRIEVE]
- Brosen K., Zeugin T., Meyer U. A. Role of P450IID6, the target of the sparteine‐debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin. Pharmacol. Ther. 1991; 49(6)609–617, [PUBMED], [INFOTRIEVE]
- Coleman T., Ellis S. W., Martin I. J., Lennard M. S., Tucker G. T. 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) is N‐demethylated by cytochromes P450 2D6, 1A2 and 3A4—implications for susceptibility to Parkinson's disease. J. Pharmacol. Exp. Ther. 1996; 277(2)685–690, [PUBMED], [INFOTRIEVE], [CSA]
- Corchero J., Granvil C. P., Akiyama T. E., Hayhurst G. P., Pimprale S., Feigenbaum L., Idle J. R., Gonzalez F. J. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol. Pharmacol. 2001; 60(6)1260–1267, [PUBMED], [INFOTRIEVE], [CSA]
- Coutts R. T., Su P., Baker G. B. Involvement of CYP2D6, CYP3A4, and other cytochrome P‐450 isozymes in N‐dealkylation reactions. J. Pharmacol. Toxicol. Methods 1994; 31(4)177–186, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Coutts R. T., Bach M. V., Baker G. B. Metabolism of amitriptyline with CYP2D6 expressed in a human cell line. Xenobiotica 1997; 27(1)33–47, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Craig D. A., Eglen R. M., Walsh L. K., Perkins L. A., Whiting R. L., Clarke D. E. 5‐Methoxytryptamine and 2‐methyl‐5‐hydroxytryptamine‐induced desensitization as a discriminative tool for the 5‐HT3 and putative 5‐HT4 receptors in guinea pig ileum. Naunyn‐Schmiedeberg's Arch. Pharmacol. 1990; 342(1)9–16, [CSA]
- Dahl M. L., Johansson I., Bertilsson L., Ingelman‐Sundberg M., Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 1995; 274(1)516–520, [PUBMED], [INFOTRIEVE], [CSA]
- Daly A. K. Molecular basis of polymorphic drug metabolism. J. Mol. Med. 1995; 73(11)539–553, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Daly A. K., Armstrong M., Monkman S. C., Idle M. E., Idle J. R. Genetic and metabolic criteria for the assignment of debrisoquine 4‐hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991; 1(1)33–41, [PUBMED], [INFOTRIEVE]
- Daly A. K., Brockmoller J., Broly F., Eichelbaum M., Evans W. E., Gonzalez F. J., Huang J. D., Idle J. R., Ingelman‐Sundberg M., Ishizaki T., Jacqz‐Aigrain E., Meyer U. A., Nebert D. W., Steen V. M., Wolf C. R., Zanger U. M. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6(3)193–201, [PUBMED], [INFOTRIEVE], [CSA]
- Dayer P., Balant L., Courvoisier F., Kupfer A., Kubli A., Gorgia A., Fabre J. The genetic control of bufuralol metabolism in man. Eur. J. Drug Metab. Pharmacokinet. 1982; 7(1)73–77, [PUBMED], [INFOTRIEVE]
- Dayer P., Leemann T., Kupfer A., Kronbach T., Meyer U. A. Stereo‐ and regioselectivity of hepatic oxidation in man—effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation. Eur. J. Clin. Pharmacol. 1986; 31(3)313–318, [PUBMED], [INFOTRIEVE]
- Dayer P., Desmeules J., Leemann T., Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4‐hydroxylation (cytochrome P‐450 dbl/bufI). Biochem. Biophys. Res. Commun. 1988; 152(1)411–416, [PUBMED], [INFOTRIEVE], [CSA]
- Dayer P., Leemann T., Striberni R. Dextromethorphan O‐demethylation in liver microsomes as a prototype reaction to monitor cytochrome P‐450 db1 activity. Clin. Pharmacol. Ther. 1989; 45(1)34–40, [PUBMED], [INFOTRIEVE], [CSA]
- de Groot M. J., Bijloo G. J., Martens B. J., van Acker F. A., Vermeulen N. P. A refined substrate model for human cytochrome P450 2D6. Chem. Res. Toxicol. 1997; 10(1)41–48, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- de Groot M. J., Ackland M. J., Horne V. A., Alex A. A., Jones B. C. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N‐dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. 1999a; 42(20)4062–4070, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- de Groot M. J., Ackland M. J., Horne V. A., Alex A. A., Jones B. C. Novel approach to predicting P450‐mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. 1999b; 42(9)1515–1524, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Droll K., Bruce‐Mensah K., Otton S. V., Gaedigk A., Sellers E. M., Tyndale R. F. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 1998; 8(4)325–333, [PUBMED], [INFOTRIEVE], [CSA]
- Ebner T., Meese C. O., Eichelbaum M. Mechanism of cytochrome P450 2D6‐catalyzed sparteine metabolism in humans. Mol. Pharmacol. 1995; 48(6)1078–1086, [PUBMED], [INFOTRIEVE], [CSA]
- Eichelbaum M. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin. Pharmacokinet. 1982; 7(1)1–22, [PUBMED], [INFOTRIEVE]
- Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N‐oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol. 1979; 16(3)183–187, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ellis S. W., Hayhurst G. P., Smith G., Lightfoot T., Wong M. M., Simula A. P., Ackland M. J., Sternberg M. J., Lennard M. S., Tucker G. T., Wolf C. R. Evidence that aspartic acid 301 is a critical substrate‐contact residue in the active site of cytochrome P450 2D6. J. Biol. Chem. 1995; 270(49)29055–29058, [PUBMED], [INFOTRIEVE]
- Ereshefsky L., Riesenman C., Lam Y. W. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin. Pharmacokinet. 1995; 29 Suppl 1: 10–18, discussion 18–19[PUBMED], [INFOTRIEVE], [CSA]
- Evans W. E., Relling M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286(5439)487–491, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet. 1980; 17(2)102–105, [PUBMED], [INFOTRIEVE]
- Evert B., Eichelbaum M., Haubruck H., Zanger U. M. Functional properties of CYP2D6 1 (wild‐type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells. Naunyn‐Schmiedeberg's Arch. Pharmacol. 1997; 355(3)309–318
- Fawcett J., Barkin R. L. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J. Affect. Disord. 1998; 51(3)267–285, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fonne‐Pfister R., Bargetzi M. J., Meyer U. A. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4‐hydroxylation. Biochem. Biophys. Res. Commun. 1987; 148(3)1144–1150, [CSA]
- Fukuda T., Nishida Y., Imaoka S., Hiroi T., Naohara M., Funae Y., Azuma J. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low‐expression but also by low affinity of CYP2D6. Arch. Biochem. Biophys. 2000; 380(2)303–308, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gaedigk A., Blum M., Gaedigk R., Eichelbaum M., Meyer U. A. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am. J. Hum. Genet. 1991; 48(5)943–950, [PUBMED], [INFOTRIEVE], [CSA]
- Galzin A. M., Eon M. T., Esnaud H., Lee C. R., Pevet P., Langer S. Z. Day‐night rhythm of 5‐methoxytryptamine biosynthesis in the pineal gland of the golden hamster (Mesocricetus auratus). J. Endocrinol. 1988; 118(3)389–397, [PUBMED], [INFOTRIEVE]
- Garcia‐Barcelo M., Chow L. Y., Chiu H. F., Wing Y. K., Lee D. T., Lam K. L., Waye M. M. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin. Chem. 2000; 46(1)18–23, [CSA]
- Ghahramani P., Ellis S. W., Lennard M. S., Ramsay L. E., Tucker G. T. Cytochromes P450 mediating the N‐demethylation of amitriptyline. Br. J. Clin. Pharmacol. 1997; 43(2)137–144, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gilham D. E., Cairns W., Paine M. J., Modi S., Poulsom R., Roberts G. C., Wolf C. R. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human fetal and adult brain by in situ hybridization. Xenobiotica 1997; 27(1)111–125, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gonzalez F. J. The CYP2D subfamily. Cytochromes P450 Metabolic and Toxicological Aspects, C. Ioannides. CRC Press, Boca Raton, FL 1996; 183–210
- Gonzalez F. J., Idle J. R. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin. Pharmacokinet. 1994; 26(1)59–70, [PUBMED], [INFOTRIEVE], [CSA]
- Gonzalez F. J., Nebert D. W. Evolution of the P450 gene superfamily: animal–plant ‘warfare,’ molecular drive and human genetic differences in drug oxidation. Trends Genet. 1990; 6(6)182–186, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gonzalez F. J., Matsunaga T., Nagata K., Meyer U. A., Nebert D. W., Pastewka J., Kozak C. A., Gillette J., Gelboin H. V., Hardwick J. P. Debrisoquine 4‐hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. DNA 1987; 6(2)149–161, [PUBMED], [INFOTRIEVE]
- Gonzalez F. J., Skoda R. C., Kimura S., Umeno M., Zanger U. M., Nebert D. W., Gelboin H. V., Hardwick J. P., Meyer U. A. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988a; 331(6155)442–446, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gonzalez F. J., Vilbois F., Hardwick J. P., McBride O. W., Nebert D. W., Gelboin H. V., Meyer U. A. Human debrisoquine 4‐hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 1988b; 2(2)174–179, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gough A. C., Miles J. S., Spurr N. K., Moss J. E., Gaedigk A., Eichelbaum M., Wolf C. R. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990; 347(6295)773–776, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Granvil C. P., Krausz K. W., Gelboin H. V., Idle J. R., Gonzalez F. J. 4‐Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J. Pharmacol. Exp. Ther. 2002; 301(3)1025–1032, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Guchhait R. B. Biogenesis of 5‐methoxy‐N,N‐dimethyltryptamine in human pineal gland. J. Neurochem. 1976; 26(1)187–190, [PUBMED], [INFOTRIEVE]
- Guengerich F. P. Role of cytochrome P450 enzymes in drug–drug interactions. Adv. Pharmacol. 1997; 43: 7–35, [PUBMED], [INFOTRIEVE]
- Guengerich F. P. Cytochrome P450s, drugs, and diseases. Mol. Interv. 2003; 3(4)8–18
- Guengerich F. P., Hanna I. H., Martin M. V., Gillam E. M. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. Biochemistry 2003; 42(5)1245–1253, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Haining R. L., Yu A. M. Cytochrome P450 pharmacogenetics. Drug Metabolizing Enzymes, J. Lee, R. S. Obach, M. B. Fisher. FontisMedia. 2003; 375–419
- Hamelin B. A., Turgeon J., Vallee F., Belanger P. M., Paquet F., LeBel M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin. Pharmacol. Ther. 1996; 60(5)512–521, [PUBMED], [INFOTRIEVE], [CSA]
- Hanioka N., Kimura S., Meyer U. A., Gonzalez F. J. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934—a base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am. J. Hum. Genet. 1990; 47(6)994–1001, [PUBMED], [INFOTRIEVE], [CSA]
- Hasler J. A. Pharmacogenetics of cytochromes P450. Mol. Aspects Med. 1999; 20(1–2)12–24; 25–137, [PUBMED], [INFOTRIEVE]
- Hattersley A. T. Maturity—onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity. Diabet. Med. 1998; 15(1)15–24, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Heim M., Meyer U. A. Genotyping of poor metabolisers of debrisoquine by allele‐specific PCR amplification. Lancet 1990; 336(8714)529–532, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Heuring R. E., Peroutka S. J. Characterization of a novel 3H‐5‐hydroxytryptamine binding site subtype in bovine brain membranes. J. Neurosci. 1987; 7(3)894–903, [PUBMED], [INFOTRIEVE]
- Hietanen E., Malaveille C., Camus A. M., Bereziat J. C., Brun G., Castegnaro M., Michelon J., Idle J. R., Bartsch H. Interstrain comparison of hepatic and renal microsomal carcinogen metabolism and liver S9‐mediated mutagenicity in DA and Lewis rats phenotyped as poor and extensive metabolizers of debrisoquine. Drug Metab. Dispos. 1986; 14(1)118–126, [PUBMED], [INFOTRIEVE]
- Hiroi T., Imaoka S., Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem. Biophys. Res. Commun. 1998; 249(3)838–843, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Horai Y., Nakano M., Ishizaki T., Ishikawa K., Zhou H. H., Zhou B. I., Liao C. L., Zhang L. M. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin. Pharmacol. Ther. 1989; 46(2)198–207, [PUBMED], [INFOTRIEVE], [CSA]
- Hoyer D., Waeber C., Pazos A., Probst A., Palacios J. M. Identification of a 5‐HT1 recognition site in human brain membranes different from 5‐HT1A, 5‐HT1B and 5‐HT1C sites. Neurosci. Lett. 1988; 85(3)357–362, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Huber J. C., Schneeberger C., Tempfer C. B. Genetic modeling of estrogen metabolism as a risk factor of hormone‐dependent disorders. Maturitas 2002; 41 Suppl 1: S55–S64, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hutzler J. M., Walker G. S., Wienkers L. C. Inhibition of cytochrome P450 2D6: structure‐activity studies using a series of quinidine and quinine analogues. Chem. Res. Toxicol. 2003; 16(4)450–459, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Idle J. R., Mahgoub A., Angelo M. M., Dring L. G., Lancaster R., Smith R. L. The metabolism of [14C]‐debrisoquine in man. Br. J. Clin. Pharmacol. 1979; 7(3)257–266, [PUBMED], [INFOTRIEVE]
- Idle J. R., Smith R. L. Pharmacogenetics in the new patterns of healthcare delivery. Pharmacogenetics 1995; 5(6)347–350, [PUBMED], [INFOTRIEVE], [CSA]
- Ingelman‐Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat. Res. 2001; 482(1–2)11–19
- Ingelman‐Sundberg M., Oscarson M., McLellan R. A. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci. 1999; 20(8)342–349, [CROSSREF]
- Johansson I., Lundqvist E., Bertilsson L., Dahl M. L., Sjoqvist F., Ingelman‐Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. U. S. A. 1993; 90(24)11825–11829, [PUBMED], [INFOTRIEVE], [CSA]
- Johansson I., Oscarson M., Yue Q. Y., Bertilsson L., Sjoqvist F., Ingelman‐Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 1994; 46(3)452–459, [PUBMED], [INFOTRIEVE], [CSA]
- Jones R. S. Tryptamine: a neuromodulator or neurotransmitter in mammalian brain?. Prog. Neurobiol. 1982; 19(1–2)117–139, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jover R., Bort R., Gomez‐Lechon M. J., Castell J. V. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus‐mediated antisense targeting. Hepatology 2001; 33(3)668–675, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kagimoto M., Heim M., Kagimoto K., Zeugin T., Meyer U. A. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J. Biol. Chem. 1990; 265(28)17209–17214, [PUBMED], [INFOTRIEVE]
- Kimura S., Umeno M., Skoda R. C., Meyer U. A., Gonzalez F. J. The human debrisoquine 4‐hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet. 1989; 45(6)889–904, [PUBMED], [INFOTRIEVE], [CSA]
- Kincaid R. L., McMullin M. M., Crookham S. B., Rieders F. Report of a fluoxetine fatality. J. Anal. Toxicol. 1990; 14(5)327–329, [PUBMED], [INFOTRIEVE], [CSA]
- Koyama E., Chiba K., Tani M., Ishizaki T. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J. Pharmacol. Exp. Ther. 1996; 278(1)21–30, [PUBMED], [INFOTRIEVE], [CSA]
- Koymans L., Vermeulen N. P., van Acker S. A., te Koppele J. M., Heykants J. J., Lavrijsen K., Meuldermans W., Donne‐Op den Kelder G. M. A predictive model for substrates of cytochrome P450‐debrisoquine (2D6). Chem. Res. Toxicol. 1992; 5(2)211–219, [PUBMED], [INFOTRIEVE]
- Krausz K. W., Yang T. J., Gonzalez F. J., Shou M., Gelboin H. V. Inhibitory monoclonal antibodies to human cytochrome P450 2D6. Biochem. Pharmacol. 1997; 54(1)15–17, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kroemer H. K., Eichelbaum M. “It's the genes, stupid.” Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci. 1995; 56(26)2285–2298, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kroemer H. K., Fischer C., Meese C. O., Eichelbaum M. Enantiomer/enantiomer interaction of (S)‐ and (R)‐propafenone for cytochrome P450IID6‐catalyzed 5‐hydroxylation: in vitro evaluation of the mechanism. Mol. Pharmacol. 1991; 40(1)135–142, [PUBMED], [INFOTRIEVE], [CSA]
- Kruger R., Vieira‐Saecker A. M., Kuhn W., Berg D., Muller T., Kuhnl N., Fuchs G. A., Storch A., Hungs M., Woitalla D., Przuntek H., Epplen J. T., Schols L., Riess O. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha‐synuclein/apolipoprotein E genotype. Ann. Neurol. 1999; 45(5)611–617, [PUBMED], [INFOTRIEVE], [CSA]
- Kupfer A., Schmid B., Preisig R., Pfaff G. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 1984; 2(8401)517–518, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lang U., Aubert M. L., Rivest R. W., Vinas‐Bradtke J. C., Sizonenko P. C. Inhibitory action of exogenous melatonin, 5‐methoxytryptamine, and 6‐hydroxymelatonin on sexual maturation of male rats: activity of 5‐methoxytryptamine might be due to its conversion to melatonin. Biol. Reprod. 1985; 33(3)618–628, [PUBMED], [INFOTRIEVE]
- Leathart J. B., London S. J., Steward A., Adams J. D., Idle J. R., Daly A. K. CYP2D6 phenotype‐genotype relationships in African–Americans and caucasians in Los Angeles. Pharmacogenetics 1998; 8(6)529–541, [PUBMED], [INFOTRIEVE], [CSA]
- Leino M., Airaksinen M. M. Methoxyindoles of the retina. Med. Biol. 1985; 63(4)160–169, [PUBMED], [INFOTRIEVE]
- Lennard M. S., Silas J. H., Freestone S., Ramsay L. E., Tucker G. T., Woods H. F. Oxidation phenotype—a major determinant of metoprolol metabolism and response. N. Engl. J. Med. 1982a; 307(25)1558–1560, [PUBMED], [INFOTRIEVE]
- Lennard M. S., Silas J. H., Freestone S., Trevethick J. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br. J. Clin. Pharmacol. 1982b; 14(2)301–303, [PUBMED], [INFOTRIEVE]
- Lewis R. V., Lennard M. S., Jackson P. R., Tucker G. T., Ramsay L. E., Woods H. F. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br. J. Clin. Pharmacol. 1985; 19(3)329–333, [PUBMED], [INFOTRIEVE]
- Libby R. T., Smith R. S., Savinova O. V., Zabaleta A., Martin J. E., Gonzalez F. J., John S. W. Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science 2003; 299(5612)1578–1581, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lightfoot T., Ellis S. W., Mahling J., Ackland M. J., Blaney F. E., Bijloo G. J., De Groot M. J., Vermeulen N. P., Blackburn G. M., Lennard M. S., Tucker G. T. Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling. Xenobiotica 2000; 30(3)219–233, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Linnet K., Olesen O. V. Metabolism of clozapine by cDNA‐expressed human cytochrome P450 enzymes. Drug Metab. Dispos. 1997; 25(12)1379–1382, [PUBMED], [INFOTRIEVE], [CSA]
- Llerena A., Cobaleda J., Benitez J. Debrisoquine hydroxylation phenotypes in healthy volunteers. Lancet 1989; 1(8651)1398, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Llerena A., Edman G., Cobaleda J., Benitez J., Schalling D., Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 1993; 87(1)23–28, [PUBMED], [INFOTRIEVE]
- Lovlie R., Daly A. K., Matre G. E., Molven A., Steen V. M. Polymorphisms in CYP2D6 duplication‐negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?. Pharmacogenetics 2001; 11(1)45–55, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet 1977; 2(8038)584–586, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Maraganore D. M., Farrer M. J., Hardy J. A., McDonnell S. K., Schaid D. J., Rocca W. A. Case‐control study of debrisoquine 4‐hydroxylase, N‐acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease. Mov. Disord. 2000; 15(4)714–719, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Marez D., Legrand M., Sabbagh N., Guidice J. M., Spire C., Lafitte J. J., Meyer U. A., Broly F. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7(3)193–202, [PUBMED], [INFOTRIEVE], [CSA]
- Martinez C., Agundez J. A., Gervasini G., Martin R., Benitez J. Tryptamine: a possible endogenous substrate for CYP2D6. Pharmacogenetics 1997; 7(2)85–93, [PUBMED], [INFOTRIEVE], [CSA]
- Masimirembwa C., Persson I., Bertilsson L., Hasler J., Ingelman‐Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br. J. Clin. Pharmacol. 1996; 42(6)713–719, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Masubuchi Y., Iwasa T., Hosokawa S., Suzuki T., Horie T., Imaoka S., Funae Y., Narimatsu S. Selective deficiency of debrisoquine 4‐hydroxylase activity in mouse liver microsomes. J. Pharmacol. Exp. Ther. 1997; 282(3)1435–1441, [PUBMED], [INFOTRIEVE], [CSA]
- Mautz D. S., Nelson W. L., Shen D. D. Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA‐expressed human P4502D6. Drug Metab. Dispos. 1995; 23(4)513–517, [PUBMED], [INFOTRIEVE], [CSA]
- McBride M. C. Bufotenine: toward an understanding of possible psychoactive mechanisms. J. Psychoact. Drugs 2000; 32(3)321–331, [CSA]
- McCann S. J., Pond S. M., James K. M., Le Couteur D. G. The association between polymorphisms in the cytochrome P‐450 2D6 gene and Parkinson's disease: a case‐control study and meta‐analysis. J. Neurol. Sci. 1997; 153(1)50–53, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McFayden M. C., Melvin W. T., Murray G. I. Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem. Pharmacol. 1998; 55(6)825–830, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McLellan R. A., Oscarson M., Seidegard J., Evans D. A., Ingelman‐Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7(3)187–191, [PUBMED], [INFOTRIEVE], [CSA]
- Mellstrom B., Bertilsson L., Lou Y. C., Sawe J., Sjoqvist F. Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation. Clin. Pharmacol. Ther. 1983; 34(4)516–520, [PUBMED], [INFOTRIEVE]
- Meyer U. A., Gut J., Kronbach T., Skoda C., Meier U. T., Catin T., Dayer P. The molecular mechanisms of two common polymorphisms of drug oxidation—evidence for functional changes in cytochrome P‐450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 1986; 16(5)449–464, [PUBMED], [INFOTRIEVE]
- Miksys S., Rao Y., Hoffmann E., Mash D. C., Tyndale R. F. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J. Neurochem. 2002; 82(6)1376–1387, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Miller G. P., Hanna I. H., Nishimura Y., Guengerich F. P. Oxidation of phenethylamine derivatives by cytochrome P450 2D6: the issue of substrate protonation in binding and catalysis. Biochemistry 2001; 40(47)14215–14223, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nadir H. H., Al‐Dabbagh S. G., Idle J. R. Elevated serum cholesterol in drug‐oxidation‐deficient rats. Biochem. Pharmacol. 1982; 31(8)1665–1668, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 1985; 38(4)402–408, [PUBMED], [INFOTRIEVE]
- Narasimhachari N., Heller B., Spaide J., Haskovec L., Fujimori M., Tabushi K., Himwich H. E. Urinary studies of schizophrenics and controls. Biol. Psychiatry 1971; 3(1)9–20, [PUBMED], [INFOTRIEVE]
- Nebert D. W. Polymorphisms in drug‐metabolizing enzymes: what is their clinical relevance and why do they exist?. Am. J. Hum. Genet. 1997; 60(2)265–271, [PUBMED], [INFOTRIEVE], [CSA]
- Nebert D. W., Russell D. W. Clinical importance of the cytochromes P450. Lancet 2002; 360(9340)1155–1162, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nelson D. R., Koymans L., Kamataki T., Stegeman J. J., Feyereisen R., Waxman D. J., Waterman M. R., Gotoh O., Coon M. J., Estabrook R. W., Gunsalus I. C., Nebert D. W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6(1)1–42, [PUBMED], [INFOTRIEVE], [CSA]
- Nordin C., Siwers B., Benitez J., Bertilsson L. Plasma concentrations of nortriptyline and its 10‐hydroxy metabolite in depressed patients—relationship to the debrisoquine hydroxylation metabolic ratio. Br. J. Clin. Pharmacol. 1985; 19(6)832–835, [PUBMED], [INFOTRIEVE]
- Oates N. S., Shah R. R., Idle J. R., Smith R. L. Genetic polymorphism of phenformin 4‐hydroxylation. Clin. Pharmacol. Ther. 1982; 32(1)81–89, [PUBMED], [INFOTRIEVE]
- Oesch F., Zimmer A., Glatt H. R. Microsomal epoxide hydrolase in different rat strains. Biochem. Pharmacol. 1983; 32(11)1783–1788, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Olesen O. V., Linnet K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA‐expressed human cytochrome P‐450 isozymes. Drug Metab. Dispos. 1997a; 25(6)740–744, [PUBMED], [INFOTRIEVE], [CSA]
- Olesen O. V., Linnet K. Metabolism of the tricyclic antidepressant amitriptyline by cDNA‐expressed human cytochrome P450 enzymes. Pharmacology 1997b; 55(5)235–243, [PUBMED], [INFOTRIEVE], [CSA]
- Oscarson M., Hidestrand M., Johansson I., Ingelman‐Sundberg M. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol. Pharmacol. 1997; 52(6)1034–1040, [PUBMED], [INFOTRIEVE], [CSA]
- Ott J. Pharmanopo‐psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J. Psychoact. Drugs 2001; 33(3)273–281, [CSA]
- Otton S. V., Crewe H. K., Lennard M. S., Tucker G. T., Woods H. F. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 1988; 247(1)242–247, [PUBMED], [INFOTRIEVE], [CSA]
- Paine M. J., McLaughlin L. A., Flanagan J. U., Kemp C. A., Sutcliffe M. J., Roberts G. C., Wolf C. R. Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J. Biol. Chem. 2003; 278(6)4021–4027, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Payami H., Lee N., Zareparsi S., Gonzales McNeal M., Camicioli R., Bird T. D., Sexton G., Gancher S., Kaye J., Calhoun D., Swanson P. D., Nutt J. Parkinson's disease, CYP2D6 polymorphism, and age. Neurology 2001; 56(10)1363–1370, [PUBMED], [INFOTRIEVE], [CSA]
- Peroutka S. J. Pharmacological differentiation and characterization of 5‐HT1A, 5‐HT1B, and 5‐HT1C binding sites in rat frontal cortex. J. Neurochem. 1986; 47(2)529–540, [PUBMED], [INFOTRIEVE]
- Raghuram T. C., Koshakji R. P., Wilkinson G. R., Wood A. J. Polymorphic ability to metabolize propranolol alters 4‐hydroxypropranolol levels but not beta blockade. Clin. Pharmacol. Ther. 1984; 36(1)51–56, [PUBMED], [INFOTRIEVE]
- Raimundo S., Fischer J., Eichelbaum M., Griese E. U., Schwab M., Zanger U. M. Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000; 10(7)577–581, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ramamoorthy Y., Yu A. M., Suh N., Haining R. L., Tyndale R. F., Sellers E. M. Reduced (±)‐3,4‐methylenedioxymethamphetamine (“Ecstasy”) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem. Pharmacol. 2002; 63(12)2111–2119, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Raynaud F., Pevet P. Determination of 5‐methoxyindoles in pineal gland and plasma samples by high‐performance liquid chromatography with electrochemical detection. J. Chromatogr. 1991a; 564(1)103–113, [PUBMED], [INFOTRIEVE]
- Raynaud F., Pevet P. Effect of different photoperiods on the diurnal rhythm of 5‐methoxytryptamine in the pineal gland of golden hamsters (Mesocricetus auratus). J. Neural Transm. Gen. Sect. 1991b; 83(3)235–242, [PUBMED], [INFOTRIEVE]
- Ritchie J. C., Idle J. R. Population studies of polymorphism in drug oxidation and its relevance to carcinogenesis. Host Factors in Human Carcinogenesis, B. Armstrong, H. Bartsch. IARC Sci. Publ., 1982; 381–394
- Rochat B., Amey M., Gillet M., Meyer U. A., Baumann P. Identification of three cytochrome P450 isozymes involved in N‐demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997; 7(1)1–10, [PUBMED], [INFOTRIEVE], [CSA]
- Rogawski M. A., Roth R. H., Aghajanian G. K. Melatonin: deacetylation to 5‐methoxytryptamine by liver but not brain aryl acylamidase. J. Neurochem. 1979; 32(4)1219–1226, [PUBMED], [INFOTRIEVE]
- Rowland K., Ellis S. W., Lennard M. S., Tucker G. T. Variable contribution of CYP2D6 to the N‐dealkylation of S‐(‐)‐propranolol by human liver microsomes. Br. J. Clin. Pharmacol. 1996; 42(3)390–393, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ryffel G. U. Mutations in the human genes encoding the transcription factors of the hepatocyte nuclear factor (HNF)1 and HNF4 families: functional and pathological consequences. J. Mol. Endocrinol. 2001; 27(1)11–29, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sachse C., Brockmoller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 1997; 60(2)284–295, [PUBMED], [INFOTRIEVE], [CSA]
- Sallee F. R., DeVane C. L., Ferrell R. E. Fluoxetine‐related death in a child with cytochrome P‐450 2D6 genetic deficiency. J. Child Adolesc. Psychopharmacol. 2000; 10(1)27–34, [PUBMED], [INFOTRIEVE], [CSA]
- Saxena R., Shaw G. L., Relling M. V., Frame J. N., Moir D. T., Evans W. E., Caporaso N., Weiffenbach B. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum. Mol. Genet. 1994; 3(6)923–926, [PUBMED], [INFOTRIEVE], [CSA]
- Schmid B., Bircher J., Preisig R., Kupfer A. Polymorphic dextromethorphan metabolism: co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation. Clin. Pharmacol. Ther. 1985; 38(6)618–624, [PUBMED], [INFOTRIEVE]
- Schoeffter P., Waeber C., Palacios J. M., Hoyer D. The 5‐hydroxytryptamine 5‐HT1D receptor subtype is negatively coupled to adenylate cyclase in calf substantia nigra. Naunyn‐Schmiedeberg's Arch. Pharmacol. 1988; 337(6)602–608
- Sellers E. M., Tyndale R. F. Mimicking gene defects to treat drug dependence. Ann. N.Y. Acad. Sci. 2000; 909: 233–246, [PUBMED], [INFOTRIEVE]
- Sellers E. M., Otton S. V., Tyndale R. F. The potential role of the cytochrome P‐450 2D6 pharmacogenetic polymorphism in drug abuse. NIDA Res. Monogr. 1997; 173: 6–26, [PUBMED], [INFOTRIEVE], [CSA]
- Shimada T., Tsumura F., Yamazaki H., Guengerich F. P., Inoue K. Characterization of (±)‐bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics 2001; 11(2)143–156, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Siddoway L. A., Thompson K. A., McAllister C. B., Wang T., Wilkinson G. R., Roden D. M., Woosley R. L. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987; 75(4)785–791, [PUBMED], [INFOTRIEVE], [CSA]
- Siegle I., Fritz P., Eckhardt K., Zanger U. M., Eichelbaum M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 2001; 11(3)237–245, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sindrup S. H., Brosen K., Gram L. F., Hallas J., Skjelbo E., Allen A., Allen G. D., Cooper S. M., Mellows G., Tasker T. C., Zussman B. D. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin. Pharmacol. Ther. 1992; 51(3)278–287, [PUBMED], [INFOTRIEVE]
- Sohn D. R., Shin S. G., Park C. W., Kusaka M., Chiba K., Ishizaki T. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br. J. Clin. Pharmacol. 1991; 32(4)504–507, [PUBMED], [INFOTRIEVE]
- Steen V. M., Molven A., Aarskog N. K., Gulbrandsen A. K. Homologous unequal cross‐over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. Hum. Mol. Genet. 1995; 4(12)2251–2257, [PUBMED], [INFOTRIEVE], [CSA]
- Strobl G. R., von Kruedener S., Stockigt J., Guengerich F. P., Wolff T. Development of a pharmacophore for inhibition of human liver cytochrome P‐450 2D6: molecular modeling and inhibition studies. J. Med. Chem. 1993; 36(9)1136–1145, [PUBMED], [INFOTRIEVE]
- Su P., Coutts R. T., Baker G. B., Daneshtalab M. Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line. Xenobiotica 1993; 23(11)1289–1298, [PUBMED], [INFOTRIEVE], [CSA]
- Sugden D., Pickering H., Teh M. T., Garratt P. J. Melatonin receptor pharmacology: toward subtype specificity. Biol. Cell 1997; 89(8)531–537, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sullivan J. P., McDonnell L., Hardiman O. M., Farrell M. A., Phillips J. P., Tipton K. F. The oxidation of tryptamine by the two forms of monoamine oxidase in human tissues. Biochem. Pharmacol. 1986; 35(19)3255–3260, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Szklarz G. D., Halpert J. R. Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. Drug Metab. Dispos. 1998; 26(12)1179–1184, [PUBMED], [INFOTRIEVE], [CSA]
- Tang W., Stearns R. A. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug–drug interactions. Curr. Drug Metab. 2001; 2(2)185–198, [PUBMED], [INFOTRIEVE]
- Tateishi T., Chida M., Ariyoshi N., Mizorogi Y., Kamataki T., Kobayashi S. Analysis of the CYP2D6 gene in relation to dextromethorphan O‐demethylation capacity in a Japanese population. Clin. Pharmacol. Ther. 1999; 65(5)570–575, [PUBMED], [INFOTRIEVE], [CSA]
- Teh L. K., Ismail R., Yusoff R., Hussein A., Isa M. N., Rahman A. R. Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J. Clin. Pharm. Ther. 2001; 26(3)205–211, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tsou A. P., Kosaka A., Bach C., Zuppan P., Yee C., Tom L., Alvarez R., Ramsey S., Bonhaus D. W., Stefanich E., Jakeman L., Eglen R. M. Cloning and expression of a 5‐hydroxytryptamine7 receptor positively coupled to adenylyl cyclase. J. Neurochem. 1994; 63(2)456–464, [PUBMED], [INFOTRIEVE]
- Tyndale R., Aoyama T., Broly F., Matsunaga T., Inaba T., Kalow W., Gelboin H. V., Meyer U. A., Gonzalez F. J. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys‐281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1991; 1(1)26–32, [PUBMED], [INFOTRIEVE]
- van Benthem J., Mans D. R., Ebels I., Balemans M. G. Rhythmic synthesis of various 5‐methoxyindoles in the pineal gland of male adult golden hamsters, kept under the same artificial conditions throughout the year. J. Neural Transm. 1985; 61(3–4)219–237, [PUBMED], [INFOTRIEVE], [CSA]
- van der Horst C. J., Ebels I. Extraction of pineal and uterine tissue at different pH values: a preliminary report on the occurrence of a few groups of compounds in both tissues. Cytobios 1980; 29(115–116)191–203, [PUBMED], [INFOTRIEVE]
- Voirol P., Jonzier‐Perey M., Porchet F., Reymond M. J., Janzer R. C., Bouras C., Strobel H. W., Kosel M., Eap C. B., Baumann P. Cytochrome P‐450 activities in human and rat brain microsomes. Brain Res. 2000; 855(2)235–243, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wainscott D. B., Cohen M. L., Schenck K. W., Audia J. E., Nissen J. S., Baez M., Kursar J. D., Lucaites V. L., Nelson D. L. Pharmacological characteristics of the newly cloned rat 5‐hydroxytryptamine2F receptor. Mol. Pharmacol. 1993; 43(3)419–426, [PUBMED], [INFOTRIEVE], [CSA]
- Wan Y. J., Poland R. E., Han G., Konishi T., Zheng Y. P., Berman N., Lin K. M. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African–Americans in southern California. Pharmacogenetics 2001; 11(6)489–499, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wang T., Roden D. M., Wolfenden H. T., Woosley R. L., Wood A. J., Wilkinson G. R. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J. Pharmacol. Exp. Ther. 1984; 228(3)605–611, [PUBMED], [INFOTRIEVE]
- Wennerholm A., Johansson I., Massele A. Y., Lande M., Alm C., Aden‐Abdi Y., Dahl M. L., Ingelman‐Sundberg M., Bertilsson L., Gustafsson L. L. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics 1999; 9(6)707–714, [PUBMED], [INFOTRIEVE], [CSA]
- Wienkers L. C. Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P‐450 enzymes and its impact on drug discovery. J. Pharmacol. Toxicol. Methods 2001; 45(1)79–84, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wolf C. R., Smith G. Pharmacogenetics. Br. Med. Bull. 1999; 55(2)366–386, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wolf C. R., Smith G., Smith R. L. Science, medicine, and the future: pharmacogenetics. BMJ 2000; 320(7240)987–990, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wolff T., Distlerath L. M., Worthington M. T., Guengerich F. P. Human liver debrisoquine 4‐hydroxylase: test for specificity toward various monooxygenase substrates and model of the active site. Arch. Toxicol. 1987; 60(1–3)89–90, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wrighton S. A., Schuetz E. G., Thummel K. E., Shen D. D., Korzekwa K. R., Watkins P. B. The human CYP3A subfamily: practical considerations. Drug Metab. Rev. 2000; 32(3–4)339–361, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wrighton S. A., VandenBranden M., Ring B. J. The human drug metabolizing cytochromes P450. J. Pharmacokinet. Biopharm. 1996; 24(5)461–473, [PUBMED], [INFOTRIEVE], [CSA]
- Yokota H., Tamura S., Furuya H., Kimura S., Watanabe M., Kanazawa I., Kondo I., Gonzalez F. J. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993; 3(5)256–263, [PUBMED], [INFOTRIEVE], [CSA]
- Yoshimoto K., Echizen H., Chiba K., Tani M., Ishizaki T. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers—N‐desisopropylation is mediated mainly by CYP1A2. Br. J. Clin. Pharmacol. 1995; 39(4)421–431, [PUBMED], [INFOTRIEVE], [CSA]
- Yu A., Haining R. L. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?. Drug Metab. Dispos. 2001a; 29(11)1514–1520, [PUBMED], [INFOTRIEVE], [CSA]
- Yu A., Haining R. L. Purification, biochemical characterization and comparative enzyme kinetics of recombinant human CYP2D6 1 and CYP2D6 2 variants. Adv. Exp. Med. Biol. 2001b; 500: 327–330, [PUBMED], [INFOTRIEVE], [CSA]
- Yu A., Dong H., Lang D., Haining R. L. Characterization of dextromethorphan O‐ and N‐demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metab. Dispos. 2001; 29(11)1362–1365, [PUBMED], [INFOTRIEVE], [CSA]
- Yu A., Kneller B. M., Rettie A. E., Haining R. L. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J. Pharmacol. Exp. Ther. 2002; 303(3)1291–1300, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yu A. M., Granvil C. P., Haining R. L., Krausz K. W., Corchero J., Kupfer A., Idle J. R., Gonzalez F. J. The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine. J. Pharmacol. Exp. Ther. 2003a; 304(2)539–546, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yu A. M., Idle J. R., Byrd L. G., Krausz K. W., Kupfer A., Gonzalez F. J. Regeneration of serotonin from 5‐methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003b; 13(3)173–181, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yu A. M., Idle J. R., Herraiz T., Kupfer A., Gonzalez F. J. Screening for endogenous substrates reveals that CYP2D6 is a 5‐methoxyindolethylamine O‐demethylase. Pharmacogenetics 2003c; 13(6)307–319, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yu A. M., Idle J. R., Krausz K. W., Kupfer A., Gonzalez F. J. Contribution of individual cytochrome P450 isozymes to the O‐demethylation of the psychotropic beta‐carboline alkaloids harmaline and harmine. J. Pharmacol. Exp. Ther. 2003d; 305(1)315–322, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yue Q. Y., Svensson J. O., Alm C., Sjoqvist F., Sawe J. Codeine O‐demethylation co‐segregates with polymorphic debrisoquine hydroxylation. Br. J. Clin. Pharmacol. 1989; 28(6)639–645, [PUBMED], [INFOTRIEVE]
- Zanger U. M., Fischer J., Raimundo S., Stuven T., Evert B. O., Schwab M., Eichelbaum M. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001; 11(7)573–585, [PUBMED], [INFOTRIEVE], [CSA]
- Zareparsi S., Kaye J., Camicioli R., Grimslid H., Oken B., Litt M., Nutt J., Bird T., Schellenberg G., Payami H. Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes. Ann. Neurol. 1997; 42(4)655–658, [PUBMED], [INFOTRIEVE], [CSA]
- Zawilska J. B., Nowak J. Z. Characterization of melatonin receptors in the brain of four avian species: duck, goose, pigeon, and turkey. Gen. Comp. Endocrinol. 1996; 101(2)227–234, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]